Premium
Granulomas in melanoma patients treated with BCG immunotherapy
Author(s) -
Hatzitheofilou Constantine,
Obenchain Dean F.,
Porter David D.,
Morton Donald L.
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820101)49:1<55::aid-cncr2820490113>3.0.co;2-f
Subject(s) - medicine , immunotherapy , bcg vaccine , melanoma , granuloma , immunocompetence , autopsy , tuberculosis , pathology , immunology , cancer , immune system , cancer research
Autopsy slides from 22 melanoma patients who received bacille Calmette‐Gúerin BCG immunotherapy and who had a postmortem examination at the UCLA Center for the Health Sciences were examined for the presence of granulomas. Granulomas were found in six patients (29%) who received BCG but not in a group of 25 melanoma patients who did not have BCG immunotherapy. A number of factors were tested for correlation with the presence of granulomas in the autopsy material. Fifty‐five percent of the patients who received BCG by both intralesional and tine technique 22 developed granulomas. No patients given BCG by the tine technique alone developed granulomas. No correlation was found between granulomas and the presence of symptoms after the administration of BCG, the duration of BCG immunotherapy, the patient's age, the number of BCG administrations, treatment with immunosuppressive agents, the length of survival after the last BCG administration, the presence of a positive PPD reaction, a positive history for granuloma‐forming diseases and tests for immunocompetence. However, these results provide evidence that the route of BCG administration strongly influences the frequency of granulomas in melanoma patients who received BCG immunotherapy.